SEVERAL

Completed

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Lead sponsor

Jose Seijas Amigo

Assets

Dulaglutide / Exenatide / GLP-1 / incretin class catch-all / Liraglutide / Lixisenatide / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

140

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≥30

Primary endpoints

•Body weight, % change•Body weight, absolute change (kg)•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05136287

Org study IDSEVERAL

Timeline

Milestones

Study first posted2021-11-29actual

Study start2022-02-01actual

Primary completion2023-11-15actual

Study completion2024-01-01actual

Last update posted2024-02-28actual

Assets

Investigational agents

Dulaglutide Exenatide GLP-1 / incretin class catch-all Liraglutide Lixisenatide Semaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Patients diagnosed with Diabetes mellitus 2 with another oral antidibetic and obesity (BMI \> 30Kg/m2) that present uncontrolled HbA1c. With a first prescription of GLP-1 receptor agonists.

Inclusion criteria

•Patients 18 years old or over

•To start with the first funded dose of GLP1 receptor agonists ( BMI > 30Kg/m2)

•Treated with another oral antidiabetic

Exclusion criteria

•Diagnosis of diabetic retinopahty and family history of thyroid cancer

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Patient-reported / QoL

Glycemic / diabetes

Safety / tolerability / PK

Weight & body composition

3 endpoints

Primary/protocol endpoint

Weight loss

Time frame:11 months

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Weight loss

Time frame:11 months

Body weight, absolute change (kg)

change from baseline, improvement

Primary/protocol endpoint

Weight loss

Time frame:11 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

HbA1c values

Time frame:11 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Patient-reported / QoL

2 endpoints

Secondary/protocol endpoint

Changes in Quality of life

Time frame:11 months

EQ-5D index

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Changes in Physical Activity

Time frame:11 months

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Number of participants experiencing adverse events

Time frame:11 months

Treatment-emergent AEs (any)

event count, event

Publications (14)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).
Clinical therapeutics2026 May 7PMID42103575doi:10.1016/j.clinthera.2026.03.012via pubmed nct search
Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.
Diabetes & metabolic syndrome2025 Sep (month)PMID41129847doi:10.1016/j.dsx.2025.103312via clinicaltrials gov reference derived + pubmed nct search
Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study.
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria2022 Aug 30PMID36520578via CT.gov background
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine2021 Mar 18PMID33567185doi:10.1056/NEJMoa2032183via CT.gov background
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet (London, England)2019 Jul 13PMID31189511doi:10.1016/S0140-6736(19)31149-3via CT.gov background
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
The lancet. Diabetes & endocrinology2018 Apr (month)PMID29397376doi:10.1016/S2213-8587(18)30024-Xvia CT.gov background
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine2017 Mar 2PMID28249135doi:10.1056/NEJMc1615712via CT.gov background
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
The New England journal of medicine2016 Jul 28PMID27295427doi:10.1056/NEJMoa1603827via CT.gov background
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine2015 Nov 26PMID26378978doi:10.1056/NEJMoa1504720via CT.gov background
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.
Diabetes care2013 Aug (month)PMID23882037doi:10.2337/dcS13-2011via CT.gov background
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
Lancet (London, England)2010 Jun 26PMID20609967doi:10.1016/S0140-6736(10)60484-9via CT.gov background
Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Pharmacology & therapeutics2009 Oct (month)PMID19545590doi:10.1016/j.pharmthera.2009.06.002via CT.gov background
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet (London, England)1998 Sep 12PMID9742976via CT.gov background
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
The New England journal of medicine1993 Sep 30PMID8366922doi:10.1056/NEJM199309303291401via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.